VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer

VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer

Show other versions (1)

Immunotherapy by blocking immune checkpoint regulators has emerged as a new targeted therapy for some cancers. Among them V-domain Ig suppressor of Tcell activation (VISTA) which is identified as a novel checkpoint regulator in ovarian cancer. This study aimed to investigate the VISTA role in Epithe...

Full description

Bibliographic Details
Main Authors: Aida Jlassi, Maroua Manai, Maram Morjen, Ghada Sahraoui, Monia Elasmi Allal, Ines ELBini-Dhouib, Lamia Naija, Lamia Charfi, Rim Rejaibi, Melika Ben Ahmed, Naziha Marrakchi, Najet Srairi-Abid, Amel Mezlini, Mohamed Manai, Karima Mrad, Raoudha Doghri
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035885/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035885/?tool=EBI

Similar Items